Ask AI
ProCE Banner Activity

neoCARHP: Phase III Trial of De-escalated Neoadjuvant Taxane + Trastuzumab and Pertuzumab ± Carboplatin in HER2+ EBC

Conference Coverage
Slideset

Phase III neoCARHP demonstrated noninferiority of a taxane + trastuzumab and pertuzumab (THP) vs taxane + carboplatin + trastuzumab and pertuzumab (TCbHP) as a de-escalated neoadjuvant strategy in patients with HER2-positive early breast cancer.

Released: June 10, 2025

Expiration: December 09, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, Gilead Sciences, Inc., Lilly, Novartis Pharmaceuticals Corporation, and Stemline Therapeutics, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Lilly

Novartis Pharmaceuticals Corporation

Stemline Therapeutics, Inc.